TY  - GEN
AU  - Gavilá,Joaquín
AU  - Oliveira,Mafalda
AU  - Pascual,Tomás
AU  - Perez-Garcia,Jose
AU  - Gonzàlez,Xavier
AU  - Canes,Jordi
AU  - Paré,Laia
AU  - Calvo,Isabel
AU  - Ciruelos,Eva
AU  - Muñoz,Montserrat
AU  - Virizuela,Juan A
AU  - Ruiz,Isabel
AU  - Andrés,Raquel
AU  - Perelló,Antonia
AU  - Martínez,Jerónimo
AU  - Morales,Serafín
AU  - Marín-Aguilera,Mercedes
AU  - Martínez,Débora
AU  - Quero,Juan C
AU  - Llombart-Cussac,Antonio
AU  - Prat,Aleix
TI  - Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
SN  - 1741-7015
PY  - 2019///0705
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Cardiotoxicity
KW  - epidemiology
KW  - Chemotherapy, Adjuvant
KW  - adverse effects
KW  - Doxorubicin
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Paclitaxel
KW  - Polyethylene Glycols
KW  - Receptor, ErbB-2
KW  - Trastuzumab
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1186/s12916-018-1233-1
ER  -